Seattle Genetics Plans to Take Ambitious Cancer Research Further

The Puget Sound region in Washington State is world renowned for its cancer research, and Bothell-based Seattle Genetics, a biotechnology company that develops and commercializes antibody-based therapies for the treatment of cancer, is set to be a notable player in this arena.

The company manufactures Adcetris, a new drug for the treatment of lymphomas which is already largely in use. In addition, Adcetris is being tried out in more than 70 trials and cancer treatment scenarios, particularly in an advanced clinical trial for the treatment of newly diagnosed or previously untreated Hodgkin lymphoma. Seattle Genetics expects Adcetris to rack up sales of $255 million to $275 million for 2016 in the U.S. and Canada.

In addition, the company has 12 new drugs in its pipeline, including one for the treatment of acute myeloid leukemia, another for the treatment of breast cancer, and two additional ones for the treatment of bladder cancer.

Seattle Genetics has been hiring around 100 employees per year for the last five years and boasts more than 800 employees. With room in its offices for another 350 employees, it is currently bolstering its hiring, particularly in operations, with plans to add 100 employees to its workforce in the U.S. and 20 additional ones to its offices in Switzerland this year.

Seattle Genetics is led by President, CEO and Chairman of the Board Dr. Clay Siegall, who co-founded it in 1998. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland and has nearly 20 years of experience in cancer research and therapeutic drug development. From 1988 to 1991 he worked at the National Cancer Institute, National Institutes of Health, then served at the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997.

Siegall is currently on the Board of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, Mirna Therapeutics and Washington Roundtable, and has been the recipient of a number of academic and entrepreneurship awards.